TPTX News and Press, Turning Point Therapeutics Inc. From 08/10/21

Earnings news remained a key theme during Tuesday's midday trading. Squarespace (NYSE:SQSP) and Oak Street Health (NYSE:OSH) both dropped following the release of their quarterly updates. Meanwhile, Turning Point Therapeutics (NASDAQ:TPTX) got a boost after it reported better-than-expected re...

The following slide deck was published by Turning Point Therapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Turning Point Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation

Turning Point Therapeutics, Inc. (TPTX) Q2 2021 Results Earnings Conference Call August 9, 2021, 04:30 PM ET Company Participants Jim Mazzola - Senior Vice President, Communication and Investor Relations Athena Countouriotis - President and Chief Executive Officer Paolo Tombesi - Executive Vi...

ACM, AMC, APPS, ATCO, CABO, CBT, CCXI, CF, CHGG, CMBM, CMP, COMP, CXW, DDD, DHT, DOOR, ELY, ESE, ETH, EVBG, FGEN, FLGT, HALO, HBM, HLIO, INO ,IPAR, MESA, MODN, NCMI, NHI, NTR, OSH, PEN, PLNT, PRPL, QLYS, RCKT, REAL, RETA, RGNX, RPAY, SAIL, SDC, STE, TPTX, VUZI, WES, ZIOP For Seeking Alpha's f...

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report second quarter financial results following the close of U.S. financial markets o...

Turning Point Therapeutics (TPTX) announces the appointment of Paolo Tombesi as the company's executive vice president and chief financial officer, effective July 26.Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple prior financial ...

SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombes...

Turning Point Therapeutics (TPTX) announces that TPX-0022 has been granted orphan drug designation by the U.S. FDA for the treatment of patients with gastric cancer, including gastroesophageal junction adenocarcinoma.TPX-0022 is a potent inhibitor of the MET tyrosine kinase and has the potent...

SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a que...

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its ...